Headquartered in Boston, MA Fiscal year ends March NYSE: HAE haemonetics.com
Haemonetics Corporation (NYSE: HAE) is a global medical technology company focused on improving the quality, effectiveness, and efficiency of health care through blood and plasma management solutions. The company operates through two primary business units: Apheresis and MedSurg. The Apheresis segment features proprietary technologies designed to enhance safety, yield, donor satisfaction, and operational efficiency for plasma and blood collectors worldwide, with Plasma being the largest sub-segment. The MedSurg segment encompasses Blood Management Technologies (including Hemostasis Management, Cell Salvage, and Transfusion Management product lines) and Interventional Technologies (including Vascular Closure systems, Sensor Guided Technologies, and Esophageal Protection products), which are designed to inform treatment decisions, optimize blood product management, and drive procedural effectiveness. The company recently acquired Vivasure to expand its interventional technologies portfolio. Updated
With consumer sentiment sitting at 53.3 in March 2026, deep in pessimistic territory, retail investors are hunting for defensive names that can grow even as households tighten budgets. Healthcare keeps that promise.…
Wednesday's top analyst upgrades and downgrades included Ally Financial, Applied Materials, CrowdStrike, Fidelity National Information Services, First Solar, Fortinet, Newmont, Occidental Petroleum, Palo Alto Networks, Take-Two Interactive Software, Trade Desk, Twilio and…
Tuesday's top analyst upgrades and downgrades included Canopy Growth, Constellation Brands, Equifax, FedEx, Franklin Resources, Micron Technology, Paramount Global, RH and T-Mobile.
These five high-conviction health care stock picks from the analysts at Jefferies all make sense for investors looking to gain exposure to a sector that should continue to do well the rest…
These four top Jefferies growth stock picks all offer investors strength in their specific industries and the ability to generate some significant portfolio alpha.
Haemonetics Corporation (NYSE: HAE) is a global medical technology company focused on improving the quality, effectiveness, and efficiency of health care through blood and plasma management solutions. The company operates through two primary business units: Apheresis and MedSurg.
24/7 Wall St.'s 12-month price target for HAE is $149.63, rated Buy. The Wall Street consensus target is $122.20. HAE price prediction →
